Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Ipratropium bromide monohydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Ipratropium bromide monohydrate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Ipravent Inhaler contains a medicine called ipratropium bromide. This belongs to a group of medicines called bronchodilators. It is used to make breathing easier for people with asthma or 'chronic obstructive pulmonary disease' (COPD), often referred to as chronic bronchitis. If you have asthma or COPD, you may have difficulty in breathing, shortness of breath, wheezing or tightness in your chest. Ipravent Inhaler works by opening up airways.

2.

What you need to know before you take it

e Ipravent Inhaler

Do not use Ipravent Inhaler:

  • If you are allergic to ipratropium bromide or any of the other ingredients of this medicine (listed in section 6).
  • If you are allergic to similar medicines which contain atropine or medicines like atropine.
  • If you are pregnant, think you are pregnant, are likely to get pregnant or are breast-feeding. Do not use if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before using Ipravent Inhaler. Warnings and precautions Talk to your doctor or pharmacist or asthma nurse before using Ipravent Inhaler if:
  • you have glaucoma, or have been told that you may develop it.
  • you have problems passing water (urine).
  • you are a man who has prostate problems.
  • you have cystic fibrosis.

If you are not sure if any of these apply to you, talk to your doctor or pharmacist or asthma nurse before using Ipravent Inhaler. Ipratropium bromide is slow acting drug and therefore you will not get immediate relief after starting this medicine. Talk to your doctor, pharmacist, or asthma nurse:

  • If you are required to take a fast-acting reliever inhaler such as salbutamol more frequently than normal or if you are not getting relief from your reliever inhaler or if your symptoms are getting worse, this may be due to worsening of asthma and you should see your doctor straightaway.
  • If your asthma seems to be getting worse you may have a bacterial infection and you must see your doctor. Your doctor may prescribe you antibiotics, may increase the dose of your inhaled corticosteroids and /or may start short course of oral corticosteroids.
  • If you experience allergic reactions like skin rash and itching (urticaria) or a severe allergic reactions (anaphylaxis) with swelling of your mouth, tongue and lips and swelling of your face, sudden difficulties in breathing (bronchospasm) and/or a tightness in your throat you must see your doctor immediately.
  • If you experience sudden difficulty in breathing, increased wheezing or shortness of breath after taking a dose of Ipravent inhaler you must stop using your Ipravent Inhaler and not use it again and you must use your fast-acting reliever inhaler straightaway.You must contact your doctor immediately.
  • If any of the spray from the inhaler accidently gets into your eyes you must contact your doctor or asthma nurse as soon as possible. Children and adolescents Ipravent inhaler should not be used in children 12 years of age and younger or adolescents 13 to 17 years of age. Other medicines and Ipravent Inhaler Tell your doctor or pharmacist if you are taking, have recently taken or might use any other medicines, including any inhalers or medicines obtained without a prescription. This includes herbal medicines. This is because Ipravent Inhaler can affect the way some other medicines work. Also some other medicines can affect the way Ipravent Inhaler works. In particular, tell your doctor or pharmacist if you are taking/have taken any of the following medicines:
  • Other inhalers to help you breathe more easily such as the reliever inhaler salbutamol.
  • Medicines called 'Xanthines' to help your breathing such as theophylline and aminophylline. If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before using Ipravent Inhaler. Pregnancy, breast-feeding and fertility If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Safety data for its use in pregnancy has not be established. You should consult your physician for more than occasional use of Ipravent Inhaler during pregnancy. It is not known whether Ipravent Inhaler is excreted in human milk. You should consult your doctor before you regular use Ipravent Inhaler during breast-feeding. The effect of Ipravent Inhaler on fertility has not been studied and there are no fertility data available. Driving and using machines You may feel dizzy, or have difficulty focusing, dilated pupils, blurred vision, visual halos and/or coloured images, red eyes, eye pain or discomfort when using Ipravent Inhaler. If any of these symptoms occur do not drive or use any tools or machines. If your eyes are affected in any way at all do not drive or operate machinery and contact your doctor straightaway.

Operations If you attend a hospital appointment or are admitted to hospital be sure to take your inhaler(s) and any other medicines (in their packaging if possible) with you. Some gases used in operations (anaesthetics gases) may affect how your inhaler works. If you are about to have surgery, make sure you mention that you are using Ipravent Inhaler to the doctor, dentist or anaesthetist. Ipravent Inhaler contains ethanol (alcohol) This medicine contains a small amount of ethanol (8.4 mg in one single dose).

3.

How to use Ipravent Inhaler

Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or asthma nurse has told you. Check with your doctor, pharmacist or asthma nurse if you are not sure. Use in children This pressurised metered dose inhaler is not to be used in children 12 years of age and younger or in adolescents 13 to 17 years of age. Use in adults (including the elderly) with either asthma or COPD

  • 1 or 2 puffs to be inhaled three or four times daily.
  • However, in early treatment some patients may need up to 4 puffs at a time to obtain maximum benefit.

Testing your inhaler When you use the inhaler for the first time you should test it to check that it works properly. Also do this if you have not used the inhaler for 3 or more days. 1. Remove the mouthpiece cover by gently pressing the sides with your thumb and index finger. 2. Point the mouthpiece away from you and press the canister twice (once at a time) to release two puffs into the air.

How to take it

your Inhaler

1. Stand or sit upright while using the Ipravent Inhaler 2. Remove the mouthpiece cover. 3. Check inside and outside the mouthpiece of the inhaler to make sure that it is clean and free from dust and dirt and any loose objects before inhaling. 4. Hold the inhaler upright between the thumb(s) on the base of the mouthpiece and a forefinger (s)/index finger(s) on the top of the inhaler (the arrow on the base of the container should be pointing upwards) and breathe out slowly and deeply. 5. Immediately after breathing out place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it 6. Breathe in slowly and deeply, through the mouth and immediately after starting to breathe in press down firmly on the top of the inhaler to release one actuation (puff) and continue to breathe in steadily and deeply. 7. Hold your breath, remove the inhaler from the mouth and take away the finger from top of the inhaler. Continue to hold your breath for as long as is comfortable, for 10 seconds if possible. 8. Breathe out slowly. Do not breathe out into the inhaler. 9. If a second inhalation is required you should wait at least one minute and then repeat steps 4 to 8. 10. Replace the mouthpiece cover after use.

IMPORTANT

  • Do not inhale too quickly, start breathing in as slowly and steadily as possible just before pressing the inhaler
  • Do not rush through the entire procedure
  • Elderly patients and patients with weak hands may use the inhaler with both hands The mouthpiece has been designed specially for use with this medicine only. Do not use any other mouthpiece with the medicine and do not use the mouthpiece provided here with any other medicine. Practice in front of a mirror the first few times. If you see "mist" coming from the top of your inhaler or the sides of your mouth you should start again. People with weak hands may find it easier to hold the inhaler with both hands. Put the two forefingers on top of the inhaler and both thumbs on the bottom below the mouthpiece. Your doctor, nurse or pharmacist will be able to advise you. The inhaler can be used with a device called Aerochamber Plus spacer. This may be useful for people who find it difficult to synchronise breathing in and inhaler actuation. Please talk to your doctor if you have difficulties to use the Ipravent Inhaler If the Inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a minimum of two minutes. When using your Ipravent Inhaler take care not to let any of the spray enter your eyes. If any of the spray from the inhaler accidently gets into your eyes you may get painful eyes, stinging or red eyes, dilated pupils, blurred vision, see colors or lights or halos around lights. If you get any of the above side effects, rinse the eye with cold tap water and immediately talk to your doctor, pharmacist or asthma nurse for further advice. Cleaning your inhaler To prevent your inhaler from getting blocked up it should be cleaned at least once a week.
  • Remove the canister and green mouthpiece cover.
  • Wash and clean the white mouthpiece in warm soapy water.
  • Rinse in warm water and allow to air dry without using any heating system.
  • Make sure the small hole in the mouthpiece is washed through thoroughly.
  • Once the mouthpiece is dry, replace the canister and the mouthpiece cover. Do not put the metal canister into water. Do not use more than your doctor has told you to use See your doctor straightaway if:
  • You feel that your inhaler is not working as well as usual. or
  • You need to use the inhaler more than your doctor has recommended. Your doctor may need to check how well your medicine is working. Your doctor may need to change your medicine. Make sure you do not run out of Ipravent Inhaler The inhaler has been designed to deliver 200 puffs of your medicine. However, it is not possible to tell when the inhaler is empty and when the 200 puffs have been used. There may still be a small amount of fluid left over in the container. Please make sure that your inhaler is replaced after you have taken 200 puffs (usually after 3-4 weeks of regular use) so that you can be certain that you are getting the right amount of your medicine in each puff.

If you use more Ipravent Inhaler than you should If you use more of this medicine than you should, talk to a doctor or go to a hospital straightaway. Take all your inhalers and any other medicines you are taking (in their packaging if possible) with you. If you take too much or too many puffs you may get a dry mouth, a rapid heart rate or blurred vision. If you forget to use your Ipravent Inhaler

  • If you forget a dose, take it as soon as you remember it.
  • However, if it is time for the next dose, skip the missed dose.
  • Do not take a double dose to make up for a forgotten dose

Do not stop using your Ipravent Inhaler unless your doctor tells you to. If you have any further questions on the use of this medicine ask your doctor or pharmacist or asthma nurse.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor straight away if you notice any of the following serious side effects – you may need urgent medical treatment:

  • If after using Ipravent Inhaler you are wheezy or have other difficulties in breathing, do not use any more (unless you have been told to by your doctor ). You may need to use a fast-acting reliever inhaler such as salbutamol to help your breathing. Your doctor may decide that you need different medicines to help your breathing.
  • Paradoxical bronchospasm (may affect up to 1 in 100 people). As with other inhaled medicines you may experience difficulty in breathing with an immediate worsening of your wheezing after taking a dose of this medicine. This is known as paradoxical bronchospasm and will respond to a fast-acting 'reliever' inhaler, your 'blue' inhaler and should be treated straightaway. You should stop using Ipravent Inhaler immediately and contact the doctor. The doctor will want to see you and examine your chest and will probably prescribe a different inhaler to treat your asthma or COPD or chronic bronchitis.
  • Allergic reactions (may affect up to 1 in 100 people) – the signs may include skin rash and itching . In severe reactions the signs include swelling of your mouth (tongue and lips) and face, sudden difficulties in breathing and a fall in your blood pressure. Tightening of your throat may occur. If allergic reactions occur, Ipravent should be stopped immediately; do not use your Ipravent Inhaler again; talk to your doctor or pharmacist straightaway.
  • Palpitations (fast or uneven heart beats ) or quickening of the heart rate (may affect up to 1 in 100 people).
  • Increased heart rate or irregular heart rhythm such as atrial fibrillation (may affect up to 1 in 1000 people).
  • If any of the spray from the inhaler accidently gets into your eyes you may get painful eyes, stinging or red eyes, dilated pupils, blurred vision, see colors or lights or halos around lights. If this happens, talk to your doctor immediately for advice. If you get problems with your eyes at any other time also talk to your doctor for advice. You may be developing increased pressure in your eyes (glaucoma), which will need treatment (straightaway). If your eyes are affected in any way do not drive or operate machinery. See your doctor straightaway if you have any of these side effects. The side effects described below have been experienced by people taking Ipravent Inhaler and they are listed as either common, uncommon or rare. Common (may affect up to 1 in 10 people)
  • Headache, dizziness
  • Dry mouth, feeling sick (nausea), stomach upset or discomfort.
  • Cough and throat irritation when you have just used Ipravent Inhaler Uncommon (may affect up to 1 in 100 people)
  • Itching, skin rash.
  • Unexpected tightness of the chest, swelling of the throat, dry throat.
  • Blurred vision, dilated pupils, increased pressure in the eye (glaucoma), painful eyes, stinging redness or swelling of the eyes, seeing colours, lights or halos around lights.
  • Diarrhoea, constipation or being sick (vomitting).
  • Mouth or lip sores.
  • Problems passing water (urine), especially if you already have problems passing urine. Rare (may affect up to 1 in 1000 people)
  • Difficulty focusing
  • Nettle rash (urticaria) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Ipravent Inhaler

Keep this medicine out of the sight and reach of children. Do not use Ipravent Inhaler after the expiry date which is stated on the carton and canister label after EXP. The expiry date refers to the last day of that month. Ipravent Inhaler should not be stored above 25oC. Keep away from direct sunlight, heat and frost. If the Inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a minimum of two minutes. The canister contains a pressurised liquid. Do not expose to temperatures higher than 50oC. Do not try to open, puncture or burn the canister even when apparently empty. Do not throw away any medicines or inhalers via waste water or household waste. Ask your pharmacist how to throw away medicines and inhalers that you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Ipravent Inhaler contains

  • The active substance is ipratropium bromide. One metered dose (ex-valve) contains 20 micrograms ipratropium bromide (as the monohydrate).This is equivalent to a delivered dose (ex-actuator) of 18 micrograms ipratropium bromide (as the monohydrate). Each canister contains 200 actuations, each actuation containing 20 micrograms ipratropium bromide (as the monohydrate).
  • The other ingredients are CFC-Free propellant, propellant HFA 134a (1,1,1,2- tetrafluoroethane), citric acid anhydrous, ethanol anhydrous and purified water. Ipravent Inhaler does not contain any chlorofluorocarbon (CFC) propellants. What Ipravent Inhaler looks like and contents of pack. Ipravent Inhaler is comprised of a pressurised aluminium canister which contains pressurised solution for inhalation sealed with a metering valve made up of a thermoplastic body and a metallic ferrule and spring

and a plastic actuator made up of polypropylene having a white mouthpiece fitted with a green mouthpiece cover. Each carton contains one inhaler. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Cipla (EU) Limited. Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom Manufacturer: S&D Pharma CZ, spol. s r.o, Theodor 28, 273 08 Pchery (Pharmos a.s. facility), Ceská Republika Cipla (EU) Limited, Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom Cipla Europe NV, De Keyserlei 58-60, Box 19, 2018 Antwerp, Belgium This leaflet was last revised in 01/2024.

Frequently asked questions about Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution

How do I take Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution?

Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution comes as inhaler containing 20mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution?

The active substance in Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution is ipratropium bromide monohydrate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Ipratropium bromide monohydrate (2 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Ipravent CFC free Inhaler is indicated for the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma.

4.2. Posology and method of administration

Posology

For inhalation use.

Children and adolescents

This pressurised metered dose inhaler is not to be used in children, 12 years of age and younger or adolescents 13 to 17 years of age.

Adults (including the elderly) with asthma or COPD

• 1 or 2 puffs to be inhaled three or four times daily.

• However, in early treatment some patients may need up to 4 puffs at a time to obtain maximum benefit.

The recommended dose should not be exceeded.

If therapy does not produce a significant improvement, if the patient's symptoms are getting worse or if a reduced response to treatment becomes apparent, medical advice must be sought. In the case of acute or rapidly worsening dyspnoea (difficulty in breathing) a doctor should be consulted immediately.

Method of administration

The correct administration of ipratropium bromide from the inhaler is essential for successful therapy. It is imperative that patient's inhaler technique should be checked to ensure optimum drug delivery of ipratropium bromide to the lungs from time to time.

It is advised to read the Patient Information Leaflet carefully before using this inhaler and to take note regarding how to use the inhaler, how to inhale from the inhaler correctly and how to clean the inhaler.

The canister should be pressed twice to release two metered doses into the air before the inhaler is used for the first time, or when the inhaler has not been used for 3 days or more, to ensure that the inhaler is working properly and that it is ready for use.

On each occasion on which the inhaler is used the following instructions should be followed:

1. Stand or sit upright while using the Ipravent Inhaler

2. Remove the mouthpiece cover.

3. Check inside and outside the mouthpiece of the inhaler to make sure that it is clean and free from dust and dirt and any loose objects before inhaling.

4. Hold the inhaler upright between the thumb(s) on the base of the mouthpiece and a forefinger(s)/index finger(s) on the top of the inhaler (the arrow on the base of the container should be pointing upwards), breathe out for as long as is comfortable, and as slowly and deeply as possible.

5. Immediately after breathing out place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it

6. Breathe in slowly and deeply, through the mouth and immediately after starting to breathe in press down firmly on the top of the inhaler to release one actuation (puff) and continue to breathe in steadily and deeply.

7. Hold the breath, remove the inhaler from the mouth and take away the finger from top of the inhaler. Continue to hold the breath for as long as is comfortable, for 10 seconds if possible.

8. Breathe out slowly Do not breathe out into the inhaler.

9. If a second inhalation is required you should wait at least one minute and then repeat steps 4 to 8.

10. Replace the mouthpiece cover after use.

IMPORTANT

• Do not inhale too quickly, start breathing in as slowly and steadily as possible just before pressing the inhaler

• Do not rush through the entire procedure

• Elderly patients and patients with weak hands may use the inhaler with both hands

• Practice inhalation technique in front of a mirror; if a mist is seen following inhalation, either from the inhaler itself or from the sides of the mouth, the inhalation procedure should be repeated

Cleaning

It is important to clean your inhaler regularly. Otherwise it may not work properly.

• Remove the canister and green mouthpiece cover.

• Wash and clean the white mouthpiece in warm soapy water.

• Rinse in warm water and allow to air dry without using any heating system.

• Make sure the small hole in the mouthpiece is washed through thoroughly.

Once the white mouthpiece is dry, replace the canister and the cap

DO NOT PUT THE METAL CANISTER INTO WATER

Please read the Patient Information Leaflet for appropriate instructions for use/inhalation

The inhaler can be used with the Aerochamber Plus spacer device. This may be useful for patients, e.g. adult, who find it difficult to synchronise breathing in and inhaler actuation.

The canister is not transparent. It is therefore not possible to see when it is empty. The inhaler will deliver 200 actuations. When these have all been used (usually after 3 - 4 weeks of regular use) the inhaler may still appear to contain a small amount of fluid. However the inhaler should be replaced in order to ensure that each metered dose contains the correct amount of medicine.

If the Inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a minimum of two minutes.

WARNING

The plastic mouthpiece has been specially designed for use with Ipravent CFC-Free Inhaler to ensure that each metered dose contains the correct amount of medicine. The mouthpiece must never be used with any other metered dose inhaler nor must Ipravent CFC-Free Inhaler be used with any mouthpiece other than the one supplied with the product.

The mouthpiece should always be kept clean (as per the cleaning procedure mentioned above)

4.3. Contraindications

Ipratropium bromide should not be used by patients with known hypersensitivity to atropine or its derivatives, or to ipratropium bromide or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Increasing use of any as required short-acting β2 adrenoceptor agonist bronchodilators to relieve asthma symptoms, lack of relief from as required short-acting β2 adrenoceptor agonist bronchodilators, short-acting bronchodilators becoming ineffective and/or increasing symptoms indicate deterioration of asthma control and patients should be reviewed by a doctor

It should be noted that an exacerbation of the clinical symptoms of asthma may be due to an acute respiratory tract bacterial infection and treatment may require appropriate antibiotics, an increase in the dose of any inhaled corticosteroids and/or a short course of oral conrticosteroids. A rapid acting, short acting inhaled β2 adrenoceptor agonist should always be available as rescue medication.

Hypersensitivity reactions following the use of ipratropium bromide have been seen and have presented as urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis.

Caution is advocated in the use of anticholinergic agents in patients predisposed to or with narrow-angle glaucoma, or with pre-existing urinary outflow tract obstruction (e.g. prostatic hyperplasia or bladder-outflow obstruction).

As patients with cystic fibrosis may be prone to gastrointestinal motility disturbances, ipratropium bromide, as other anticholinergics, should be used with caution in these patients.

There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, narrow-angle glaucoma, eye pain) when aerosolised ipratropium bromide, either alone or in combination with a β2 adrenoceptor agonist, has come into contact with the eyes. Thus patients must be instructed in the correct administration of ipratropium bromide and warned against the accidental release of the contents of the inhaler into the eye. Since ipratropium bromide is inhaled via a mouthpiece and with manual control, the risk of the mist entering the eyes is limited. Antiglaucoma therapy is effective in the prevention of acute narrow-angle glaucoma in susceptible individuals and patients who may be susceptible to glaucoma should be warned specifically on the need for ocular protection.

Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop, treatment with miotic drops should be initiated and specialist advice sought immediately.

Patients should be informed when starting treatment that the onset of action of ipratropium bromide is slower than that of inhaled sympathomimetic bronchodilators.

As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid –acting inhaled bronchodilator and should be treated straightaway. Ipravent CFC-Free Inhaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

This medicinal product contains a small amount of ethanol (8.4 mg in one single dose).

Ipratropium bromide has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in these patient populations

4.5. Interaction with other medicinal products and other forms of interaction

There is evidence that the administration of ipratropium bromide with beta-adrenergic medicinal products and xanthine preparations may produce an additive bronchodilatory effect.

4.6. Fertility, pregnancy and lactation

There is no experience of the use of this product in pregnancy and lactation in humans. It should not be used in pregnancy or lactation unless the expected benefits to the mother are thought to outweigh any potential risks to the fetus or neonate.

Pregnancy

The safety of ipratropium bromide during human pregnancy has not been established. The benefits of using ipratropium bromide during a confirmed or suspected pregnancy must be weighed against the possible hazards to the unborn child. Preclinical studies have shown no embryotoxic or teratogenic effects following inhalation or intranasal application at doses considerably higher than those recommended in man.

Breastfeeding

It is not known whether ipratropium bromide is excreted into breast milk. It is unlikely that ipratropium bromide would reach the infant to an important extent, however caution should be exercised when ipratropium bromide is administered to nursing mothers.

Studies of HFA-134a administered to pregnant and lactating rats and rabbits have not revealed any special hazard.

Fertility

Preclinical studies performed with ipratropium bromide showed no adverse effect on fertility (see section 5.3). Clinical data on fertility are not available for ipratropium bromide. Therefore in case of planned pregnancy the product should be used with caution after consultation with doctor.

4.7. Effects on ability to drive and use machines

Ipratropium bromide has a moderate influence on the ability to drive or use machines.

No studies on the effects on the ability to drive and use machines have been performed. However patients should be advised that they may experience undesirable effects such as dizziness, accommodation disorder, mydriasis, blurred vision, visual halos and/or coloured images, red eyes, eye pain or discomfort during treatment with ipratropium bromide. If patients experience the above mentioned side effects they should avoid potentially hazardous tasks such as driving or operating machinery and should contact their doctor straightaway.

If the eyes are affected in any way at all do not drive or operate machinery. Contact your doctor.

4.8. Undesirable effects

Many of the listed undesirable effects can be assigned to the anticholinergic properties of ipratropium bromide. As with all inhalation therapy ipratropium bromide may show symptoms of local irritation.

Adverse drug reactions were identified from data obtained in clinical trials and pharmacovigilance during post approval use of the medicinal product.

The most frequent side effects known from clinical trials were headache, throat irritation, cough, dry mouth, gastro-intestinal motility disorders (including constipation, diarrhea and vomiting), nausea, and dizziness.

Frequencies

Very common ≥ 1/10

Common ≥ 1/100 to < 1/10

Uncommon ≥ 1/1,000 to < 1/100

Rare ≥ 1/10,000 to < 1/1,000

Very rare < 1/10,000

Immune system disorder

Hypersensitivity (1)

Uncommon

Anaphylactic reaction

Uncommon

Angioedema of tongue, lips and face

Uncommon

Nervous system disorders

Headache

Common

Dizziness

Common

Eye disorders

Blurred vision

Uncommon

Mydriasis (2)

Uncommon

Intraocular pressure increased (2)

Uncommon

Glaucoma (2)

Uncommon

Eye pain (2)

Uncommon

Halo vision

Uncommon

Conjunctival hyperaemia

Uncommon

Corneal oedema

Uncommon

Accommodation disorder

Rare

Cardiac disorders

Palpitations

Uncommon

Supraventricular tachycardia

Uncommon

Atrial fibrillation

Rare

Heart rate increased

Rare

Respiratory, thoracic and mediastinal disorders

Throat irritation

Common

Cough

Common

Bronchospasm

Uncommon

Paradoxical bronchospasm(3)

Uncommon

Laryngospasm

Uncommon

Pharyngeal oedema

Uncommon

Dry throat

Uncommon

Gastro-intestinal disorders

Dry mouth

Common

Nausea

Common

Gastro-intestinal motility disorder

Common

e.g. Diarrhoea

Uncommon

Constipation

Uncommon

Vomiting

Uncommon

Stomatitis

Uncommon

Skin and subcutaneous tissue disorders

Rash

Uncommon

Pruritus

Uncommon

Urticaria

Rare

Renal and urinary disorders

Urinary retention (4)

Uncommon

(1) Hypersensitivity reactions following the use of ipratropium bromide have been seen and have presented as urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis. If severe allergic reactions occur, ipratropium bromide should be discontinued immediately, do not use your Ipravent CFC-Free Inhaler again, talk to your doctor or pharmacist immediately.

(2) Ocular complications have been reported when aerolised ipratropium bromide, either alone or in combination with an β2 adrenoceptor agonist, has come into contact with the eyes - see section 4.4.

(3) As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid –acting inhaled bronchodilator and should be treated straightaway. Ipratropium bromide should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

(4) The risk of urinary retention may be increased in patients with pre-existing urinary outflow tract obstruction.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

No symptoms specific to overdosage have been encountered. In view of the wide therapeutic window and topical administration of ipratropium bromide, no serious anticholinergic symptoms are to be expected. As with other anticholinergics, dry mouth, visual accommodation disturbances and tachycardia would be the expected symptoms and signs of overdose.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • IPRAVENT INHALER 20 micrograme/doza prescriptionIPRATROPII BROMIDUM · inhaler / nebuliser
  • IPRATOM 250mcg/2ml prescriptionIPRATROPII BROMIDUM · inhaler / nebuliser
  • IPRATOM 500 mcg/2ml prescriptionIPRATROPII BROMIDUM · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • AtroventIpratropii bromidum · inhaler / nebuliser
  • Atrovent NIpratropii bromidum · inhaler / nebuliser
  • AtrodilIpratropii bromidum · inhaler / nebuliser
  • Ipravent InhalerIpratropii bromidum · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Ipratropium bromide monohydrate

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →